Michael Barbella, Managing Editor11.03.23
Inogen Inc. has appointed Mike Sergesketter as interim chief financial officer (CFO) to succeed Kristin Caltrider, who stepped down for personal reasons. Caltrider’s decision was not related to any disagreements with the company or its management on any matters relating to its operations, policies, or practices.
“I would like to thank Kristin for her contributions to Inogen and share my optimism for the future of the company as we continue our strategic evolution to become a more prominent player in respiratory care," Inogen President/CEO Nabil Shabshab said. "Mike has brought value to Inogen as an accomplished CFO and partner to me, and I am pleased to welcome him back to the company. His decades of experience across finance, M&A, and strategic manufacturing, as well as his track record of being a partner and advisor cross-functionally are strong assets as we continue to execute against our 2023 plans and prepare for 2024.”
Inogen has retained an executive search firm to help with the search for a permanent replacement.
Sergesketter has more than 40 years of finance experience in the manufacturing services industry. He brings expertise working across business functions, including with the CEO and Board of Directors, Audit Committee and Compensation and Governance Committee. Sergesketter last served as Inogen's interim CFO between December 2021 and March 2022, and previously served as CFO of Kimball Electronics Inc., where he helped develop and execute the company’s globalization strategy while also building a robust finance function to support the its growth. During his tenure at Kimball Electronics and its predecessors, Sergesketter was responsible for various critical finance functions, including SEC reporting, treasury, investor relations, tax, financial planning and analysis, and internal audit while playing a leading role in various M&A transactions in the United States and abroad.
Inogen is reaffirming expectations for $315 million to $320 million in annual revenue this year and $20 million to $25 million adjusted EBITDA loss.
Inogen offers respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.
“I would like to thank Kristin for her contributions to Inogen and share my optimism for the future of the company as we continue our strategic evolution to become a more prominent player in respiratory care," Inogen President/CEO Nabil Shabshab said. "Mike has brought value to Inogen as an accomplished CFO and partner to me, and I am pleased to welcome him back to the company. His decades of experience across finance, M&A, and strategic manufacturing, as well as his track record of being a partner and advisor cross-functionally are strong assets as we continue to execute against our 2023 plans and prepare for 2024.”
Inogen has retained an executive search firm to help with the search for a permanent replacement.
Sergesketter has more than 40 years of finance experience in the manufacturing services industry. He brings expertise working across business functions, including with the CEO and Board of Directors, Audit Committee and Compensation and Governance Committee. Sergesketter last served as Inogen's interim CFO between December 2021 and March 2022, and previously served as CFO of Kimball Electronics Inc., where he helped develop and execute the company’s globalization strategy while also building a robust finance function to support the its growth. During his tenure at Kimball Electronics and its predecessors, Sergesketter was responsible for various critical finance functions, including SEC reporting, treasury, investor relations, tax, financial planning and analysis, and internal audit while playing a leading role in various M&A transactions in the United States and abroad.
Inogen is reaffirming expectations for $315 million to $320 million in annual revenue this year and $20 million to $25 million adjusted EBITDA loss.
Inogen offers respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.